TC
BTAI icon

TwinBeech Capital’s BioXcel Therapeutics BTAI Stock Holding History

TwinBeech Capital’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-547
Closed -$254K – 586
2021
Q2 		$254K Buy
+547
New +$298K 0.03% 395
2021
Q1 		– Sell
-282
Closed -$208K – 462
2020
Q4 		$208K Buy
+282
New +$220K 0.03% 406

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TwinBeech Capital's BTAI Position: Q3 2021 in Review

TwinBeech Capital sold out of BioXcel Therapeutics (BTAI) in Q3 2021, closing a stake of 547 shares — an estimated $254K sold.

TwinBeech Capital first reported a position in BTAI in Q4 2020 and held it in 2 quarters. The position peaked at $254K in Q2 2021. 103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

  • TwinBeech Capital reported no remaining BioXcel Therapeutics position as of Q3 2021 after selling out during the quarter.
  • TwinBeech Capital sold 547 BioXcel Therapeutics shares in Q3 2021, an estimated $254K.
  • TwinBeech Capital first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 2 quarters.
  • TwinBeech Capital's BioXcel Therapeutics position peaked at $254K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.